Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vaccination group | Lung cancer patients receive 23-valent pneumonia vaccine |
| |
| Unvaccinated group | Lung cancer patients have not received the 23-valent pneumococcal vaccine |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 23-valent pneumococcal vaccine | Biological | Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine |
|
| Measure | Description | Time Frame |
|---|---|---|
| The incidence of pneumonia at 12 months | During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests. | 12 months |
| Incidence of pneumonia | The proportion of lung cancer patients who developed pneumonia during the study period. | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Survival rate | The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years). | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Lung cancer-related complications | The incidence of complications related to lung cancer (such as respiratory failure, infection, etc.). | 5 years |
| Length of hospital stay | Record the number of days of hospitalization for patients hospitalized due to lung infection. |
Inclusion Criteria:
Exclusion Criteria:
Patients having other factors that preventing researchers from enrollment them.
Not provided
Not provided
Not provided
Lung cancer patients can receive or not receive the 23-valent pneumococcal vaccine
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C414006 | 23-valent pneumococcal capsular polysaccharide vaccine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years |
| Hospitalization rate | The proportion of patients hospitalized due to pneumonia or other related complications. | 5 years |
| Antibiotic usage | This includes the types, dosages, and durations of antibiotic usage, etc | 5 years |
| Quality of life of lung cancer patients | Specific quality of life assessment scales are used, such as standardized quality of life assessment tools (such as EORTC QLQ-C30) to evaluate the quality of life of patients. | 5 years |
| Immune response | The immune response (such as antibody levels) of patients after vaccination is evaluated through serological testing. | 5 years |
| Adverse reactions after vaccination | Observe whether patients who receive the 23-valent pneumococcal vaccine experience adverse reactions after vaccination, such as fever, redness, swelling and pain at the injection site, headache, dizziness, etc. | 30 days |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |